Remaining Unmet Needs in Frontline Maintenance Therapy and Ongoing Trials for mUC

“How do we personalize and improve patient selection for frontline treatment now that patients are living, on average, more than 2 years with this aggressive cancer?” said David H. Aggen, MD, PhD

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Disease-free survival and overall survival were lower with extended lymphadenectomy compared with standard lymphadenectomy.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

The decision is backed by robust efficacy data from the phase 3 ENVISION trial, evaluating UGN-102 in patients with non-muscle invasive bladder cancer.

TAR-200 plus cetrelimab did not yield significant results vs chemoradiation in muscle-invasive bladder cancer.